### Contraceptive methods

|-----------|-----------------------|--------------------------|----------------------|------------------------|-----------------
| N/A       | Suprelorin EGZAC®  (1 record) | N/A                     | N/A                  | N/A                    | N/A             
| Ovariohysterectomy/Ovariectomy/Tubal ligation | N/A                     | N/A                     | N/A                  | N/A                    | N/A             

### Commercial Name:

| Suprelorin * 5 (1 record) | Lupron * 6 (records) | Implanon® Neplanon® (8 records) | N/A | N/A |

### Product Availability:

| 4.7mg (Suprelorin 4) and 9.4 mg (Suprelorin 12) widely available through veterinary drug distributors in the EU. | Luprolide acetate licensed for human use | Manufactured by Bayer Schering Pharma. Available through human drug distributors | Manufactured by Organon. Available through human drug distributors | Manufactured by Pfizer. Widely available throughout Europe through human drug distributors | N/A |

### Restrictions and/or permit required by Importing Country:

- EGZAC recommends: always check with your local licensing authority
- Data deficient
- EGZAC recommends: always check with your local licensing authority
- EGZAC recommends: always check with your local licensing authority
- EGZAC recommends: always check with your local licensing authority
- N/A

### Mechanism of action:

- GnRH agonist suppresses the hypothalamic-pituitary-gonadal axis, which reduces the production of gonadotropin hormones.
- GnRH agonist suppresses the reproductive endocrine system, preventing production of phytoestrogens.
- GnRH agonist inhibits the pituitary gland, reducing the production of gonadotropin hormones.
- GnRH agonist reduces the production of endogenous gonadotropins.
- GnRH agonist reduces the production of endogenous gonadotropins.

### Insertion/Placement:

- Sub-cutaneous, in a place where it can be easily detected for removal at later date (e.g. upper inner arm). Refer to Suprelorin fact sheet for detailed information.
- Injectable
- Intramuscular or subcutaneous. EGZAC recommends sub-cutaneous, upper outer arm for visibility and easier retrieval.
- Injectable subcutaneous
- Injectable subcutaneous - do not inject intramuscularly as into subcutaneous fat or scar tissue
- Surgical

### Dose:

- Dosage information is not available. Consultation from human literature is likely the best place to start. Please contact EGZAC for dosage recommendations.
- Data deficient. Our database suggests dosages between 0.15 to 0.37 of an implant depending on species and weight. Please contact EGZAC for dosage recommendations.
- Data deficient. 2 rods of Norplant/ 1 rod Norplant-2 depending on species and weight. Please contact EGZAC for dosage recommendations.
- Data deficient. 2-5 mg/kg body weight every 2-3 months. For capybara (Hydrochaeris hydrochaeris) a higher dosage seems to be required (~25mg/kg) from information in our database. Please contact EGZAC for dosage recommendations.
- Data deficient. Product dosage is 1.0-1.5 mL for individuals >50 kg. This dosage is only advisable in a short-term contraceptive e.g. to suppress post-puberty estrus. Introduction of newly vasectomised males. Repeat use not advised. Please contact EGZAC for dosage recommendations.

### Animal name:

Orycteropodidae, Ochotonidae and Rodentia

Fact Sheet Compiled by: Veronica Cowl
Fact Sheet Reviewed by: Gidona Goodman & Tai Strike
Last Updated: June 2017

We would recommend supplementing any contraceptive boost with behavioural and hormone monitoring. For more information on this, please contact contraception@chesterzoo.org
### Oestrus cycles during contraceptive treatment:

Initial oestrus and ovulation (during the 3-weeks of stimulation) may occur and then no-oestrus cycle. To suppress the initial oestrus and ovulation with the concomitant progesterone production and the associated deleterious effects of this you MUST follow the megestrol acetate protocol mentioned above.

#### Duration

Duration of efficacy has not been well established as a guide. 4.7 mg implants will suppress for a minimum of 6 months, 9.4 mg will be effective for a minimum of 12 months.

#### Data deficient in this group.

#### Reversibility

Deslorelin is considered reversible. 1 example of reversal is the use of a reversible intra-abdominal technique. It is recommended to remove the implant to aid reversibility.

#### Effects on Behaviour

Data deficient.

#### Effects on sexual physical characteristics

Data deficient.

### Use in prepubertals or juveniles:

Data deficient, should start at least 1 month prior to the breeding season.

### Use in seasonal breeders:

Data deficient, Not well-established, duration of effect likely related to the dose. Higher doses result in longer duration of effect. Lupron® is available in various formulations lasting from 1 to 6 months, but because the release of hormone from the depot formulation varies by individual, actual duration of efficacy can vary considerably.

### Use during pregnancy:

Data deficient.

### Use during lactation:

Data deficient.

### Use in prepubertals or juveniles:

Data deficient.

### Males

Data deficient.

### Dose

Data deficient. Our database suggests 3 implants should be sufficient for individuals ≤75kg. For heavier individuals, 2 implants are advised. Please contact EGZAC for dosage recommendations.

### Latency to effectiveness

Data deficient.

### Data sheet

Data deficient in this group, see product information sheet.
### Use in prepubertal or juveniles:

- Data deficient in this group, see product information sheet.

### Use in seasonal breeders:

- Data deficient. Should start at least 2 months prior to the breeding season.

### Duration and Reversibility

<table>
<thead>
<tr>
<th>Data deficient in this group, see product information sheet.</th>
</tr>
</thead>
</table>

### Effects on Behaviour

<table>
<thead>
<tr>
<th>Data deficient in this group, see product information sheet.</th>
</tr>
</thead>
</table>

### Effects on sexual physical characteristics

| Data deficient in these taxa. Likely that some dichromatic species may change colour if testosterone related. Decrease in body size, feminisation of males. |
| Data deficient in these taxa. Likely that body size may decrease, decrease testicular size, feminisation of males. Similar to gonadectomy but reversible. |
| Data deficient. Same as deslorelin. |

### General:

<table>
<thead>
<tr>
<th>Data deficient.</th>
</tr>
</thead>
</table>

### Side effects

- A more recently developed Suprelorin®/deslorelin protocol using Ovarid®/Megace®/megestrol acetate to prevent the initial stimulation phase, followed by implant removal when reversal is desired, may be a safer contraceptive option.

### Warnings

- Causes initial gonadal stimulation that MUST be suppressed (see above); correct administration essential - see product information sheet.

---

**Side effects:** A more recently developed Suprelorin®/deslorelin protocol using Ovarid®/Megace®/megestrol acetate to prevent the initial stimulation phase, followed by implant removal when reversal is desired, may be a safer contraceptive option.

**Warnings:** Causes initial gonadal stimulation that MUST be suppressed (see above); correct administration essential - see product information sheet.

---

**Reference:**

1. **Control of Reproduction in Ferrets, Rabbits and Rodents. E Bic, Reproduction in Domestic Animals 81-86 (2014)**


**Disclaimer:** EGZAC endeavours to provide correct and current information on contraception from various sources. As these are prescriptions only medicines it is the responsibility of the veterinarian to determine the dosage and best treatment for an individual.